Want to see JP:6523 full AI Analyst Report?
PHC Holdings Corp. (6523) AI Stock Analysis
PHC Holdings Corp.
(TSE/TYO:6523)
The overall score is driven primarily by the company's robust cash flow and improving balance sheet, which provide financial stability. However, the score is significantly constrained by extremely weak net profitability and low return on equity. Technicals show a stock consolidating in a longer-term uptrend, while the valuation is fair with a solid dividend yield.
PHC Holdings Corp. (6523) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 180.17B
- Dividend Yield
- 2.97%
- Average Volume (3M)
- 1.13M
- Price to Earnings (P/E)
- 19.5
- Beta (1Y)
- 0.78
- Revenue Growth
- 3.04%
- EPS Growth
- -19.26%
- Country
- Japan
- Employees
- 8,647
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
PHC Holdings Corp. Business Overview & Revenue Model
Company Description
PHC Holdings Corporation, through its network of subsidiaries, specializes in the innovation, production, and sale of medical instruments, advanced healthcare technology solutions, and life science merchandise. The company's product line includes blo...
How the Company Makes Money
PHC Holdings primarily makes money by selling healthcare and life-science products and related consumables to hospitals, clinics, laboratories, research institutions, and distributors, generating revenue from both (1) capital equipment sales and (2)...
PHC Holdings Corp. Financial Statement Overview
Summary
Strong cash flow generation (Score 70) and an improving balance sheet (Score 55) are offset by very weak profitability (Score 45). Net margins are razor-thin at 0.14%, and return on equity is low, indicating the company is not efficiently converting revenue into profit despite healthy gross margins.
Income Statement
45NeutralBalance Sheet
55NeutralCash Flow
70Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 371.22B | 364.40B | 361.59B | 353.90B | 356.43B | 340.45B |
| Gross Profit | 170.27B | 165.26B | 166.22B | 157.97B | 169.13B | 165.24B |
| EBITDA | 54.54B | 47.72B | 52.33B | 30.15B | 36.76B | 37.56B |
| Net Income | 9.17B | 492.00M | 10.48B | -12.89B | -3.22B | -8.46B |
Balance Sheet | ||||||
| Total Assets | 543.08B | 542.51B | 532.48B | 564.33B | 561.57B | 591.32B |
| Cash, Cash Equivalents and Short-Term Investments | 41.28B | 39.82B | 43.90B | 51.82B | 63.25B | 97.63B |
| Total Debt | 229.26B | 234.56B | 269.26B | 300.28B | 307.24B | 323.32B |
| Total Liabilities | 374.61B | 381.63B | 391.31B | 425.16B | 422.74B | 455.25B |
| Stockholders Equity | 169.31B | 161.67B | 141.64B | 139.51B | 138.01B | 135.37B |
Cash Flow | ||||||
| Free Cash Flow | 41.83B | 33.37B | 30.33B | 26.67B | 9.86B | 39.32B |
| Operating Cash Flow | 51.41B | 42.46B | 41.94B | 41.30B | 21.38B | 51.05B |
| Investing Cash Flow | -9.70B | -8.45B | -8.47B | -23.68B | -17.52B | -12.52B |
| Financing Cash Flow | -39.29B | -39.82B | -39.07B | -36.53B | -40.83B | -7.01B |
PHC Holdings Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6523, the sentiment is Positive. The current price of 1405.00 is below the 20-day moving average (MA) of 1416.30, below the 50-day MA of 1412.84, and above the 200-day MA of 1146.40, indicating a neutral trend. The MACD of -17.43 indicates Positive momentum. The RSI at 53.36 is Neutral, neither overbought nor oversold. The STOCH value of 88.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6523.
PHC Holdings Corp. Peers Comparison
Overall Rating
JP:667882Outperform
JP:796364Neutral
JP:684960.5Neutral
JP:652360Neutral
JP:454950Neutral
JP:760047Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 18.42B | 12.22 | ― | 5.97% | 20.88% | 44.61% | |
| 64Neutral | JPY 8.49B | 10.10 | ― | 2.90% | 9.02% | 8.88% | |
| 61Neutral | JPY 265.01B | 19.32 | ― | 1.98% | 1.43% | 1.86% | |
| 60Neutral | JPY 180.17B | 19.53 | 5.76% | 2.97% | 3.04% | -19.26% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 76.06B | 41.05 | ― | 2.51% | 3.92% | -52.01% | |
| 47Neutral | JPY 15.22B | -69.06 | ― | 2.94% | -6.64% | 67.08% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6523 | PHC Holdings Corp. | 1415.00 | 422.43 | 42.56% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2307.00 | -26.34 | -1.13% | |
| JP:6678 | Techno Medica Co., Ltd. | 2161.00 | 334.37 | 18.31% | |
| JP:6849 | Nihon Kohden Corporation | 1616.50 | -130.88 | -7.49% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 578.00 | 98.50 | 20.54% | |
| JP:7963 | Koken Ltd. | 1727.00 | -96.08 | -5.27% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026